Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with stable coronary artery disease, it remains unclear whether an initial management strategy of percutaneous coronary intervention (PCI) with intensive pharmacologic therapy and lifestyle intervention (optimal medical therapy) is superior to optimal medical therapy alone in reducing the risk of cardiovascular events. METHODS: We conducted a randomized trial involving 2287 patients who had objective evidence of myocardial ischemia and significant coronary artery disease at 50 U.S. and Canadian centers. Between 1999 and 2004, we assigned 1149 patients to undergo PCI with optimal medical therapy (PCI group) and 1138 to receive optimal medical therapy alone (medical-therapy group). The primary outcome was death from any cause and nonfatal myocardial infarction during a follow-up period of 2.5 to 7.0 years (median, 4.6). RESULTS: There were 211 primary events in the PCI group and 202 events in the medical-therapy group. The 4.6-year cumulative primary-event rates were 19.0% in the PCI group and 18.5% in the medical-therapy group (hazard ratio for the PCI group, 1.05; 95% confidence interval [CI], 0.87 to 1.27; P=0.62). There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, and stroke (20.0% vs. 19.5%; hazard ratio, 1.05; 95% CI, 0.87 to 1.27; P=0.62); hospitalization for acute coronary syndrome (12.4% vs. 11.8%; hazard ratio, 1.07; 95% CI, 0.84 to 1.37; P=0.56); or myocardial infarction (13.2% vs. 12.3%; hazard ratio, 1.13; 95% CI, 0.89 to 1.43; P=0.33). CONCLUSIONS: As an initial management strategy in patients with stable coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy. (ClinicalTrials.gov number, NCT00007657 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The screening of asymptomatic individuals with high ASCVD risk is not recommended (Fig. 10.5), in part because these high-risk people should already be receiving intensive medical therapy-an approach that provides benefits similar to those of invasive revascularization (208,209).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“The screening of asymptomatic individuals with high ASCVD risk is not recommended, in part because these high-risk people should already be receiving intensive medical therapy—an approach that provides benefits similar to those of invasive revascularization (197,198).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [197]
In the citing paper
“OMT with risk modification remains the foundation of management in patients with T2DM and CAD.263,264”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [264]
In the citing paper
“these high-risk patients should already be receiving intensive medical therapy -an approach that provides benefi t similar to invasive revascularization (172,173).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [172]
In the citing paper
“The screening of asymptomatic patients remains controversial, especially as intensive medical therapy indicated in diabetic patients at high risk for CVD has an increasing evidence base for providing equal outcomes to invasive revascularization, including in diabetic patients (222).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [222]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Self-citationThe SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Keeley, E. C., Boura, J. A., & Grines, C. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12113-7 · Cited by 4,361
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Rosamond, W., Flegal, K., Friday, G., Furie, K., Go, A., Greenlund, K., Haase, N., Ho, M., Howard, V., Kissela, B., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.179918 · Cited by 3,277
de Lorgeril, M., Salen, P., Martin, J.-L., Monjaud, I., Delaye, J., & Mamelle, N. (1999) · Circulation · doi:10.1161/01.cir.99.6.779 · Cited by 2,910
Naghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087481.55887.c9 · Cited by 2,668
Naghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087480.94275.97 · Cited by 2,270
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R., Frey, M. J., Lakkis, N., Neumann, F.-J., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,103
Self-citationGibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., Deedwania, P. C., Douglas, J. S., Ferguson, T. B., Fihn, S. D., Fraker, T. D., Gardin, J. M., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02848-6 · Cited by 1,689
Self-citationSafety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone, G. W., Moses, J. W., Ellis, S. G., Schofer, J., Dawkins, K. D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E., Kirtane, A. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067193 · Cited by 1,631
Little, W. C., Constantinescu, M., Applegate, R. J., Kutcher, M. A., Burrows, M. T., Kahl, F. R., & Santamore, W. P. (1988) · Circulation · doi:10.1161/01.cir.78.5.1157 · Cited by 1,474
Angiographic progression of coronary artery disease and the development of myocardial infarction
Ambrose, J. A., Tannenbaum, M. A., Alexopoulos, D., Hjemdahl-Monsen, C. E., Leavy, J., Weiss, M., Borrico, S., Gorlin, R., & Fuster, V. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90356-7 · Cited by 1,452
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
An overview of randomized trials of rehabilitation with exercise after myocardial infarction.
O'Connor, G. T., Buring, J. E., Yusuf, S., Goldhaber, S. Z., Olmstead, E. M., Paffenbarger, R. S., & Hennekens, C. H. (1989) · Circulation · doi:10.1161/01.cir.80.2.234 · Cited by 1,414
Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Lagerqvist, B., James, S. K., Stenestrand, U., Lindbäck, J., Nilsson, T., & Wallentin, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067722 · Cited by 1,197
Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Kastrati, A., Mehilli, J., Pache, J., Kaiser, C., Valgimigli, M., Kelbæk, H., Menichelli, M., Sabaté, M., Suttorp, M. J., Baumgart, D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067484 · Cited by 1,006
Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease
Pitt, B., Waters, D., Brown, W. V., van Boven, A. J., Schwartz, L., Title, L. M., Eisenberg, D., Shurzinske, L., & McCormick, L. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907083410202 · Cited by 946
Self-citationFox, K., Poole-Wilson, P., Henderson, R., Clayton, T., Chamberlain, D., Shaw, T., Wheatley, D., & Pocock, S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09894-x · Cited by 901
Mehta, S. R., Cannon, C. P., Fox, K. A. A., Wallentin, L., Boden, W. E., Spacek, R., Widimsky, P., McCullough, P. A., Hunt, D., Braunwald, E., et al. (2005) · JAMA · doi:10.1001/jama.293.23.2908 · Cited by 827
Self-citationParisi, A. F., Folland, E. D., & Hartigan, P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260102 · Cited by 736
Self-citationCoronary Intervention for Persistent Occlusion after Myocardial Infarction
Hochman, J. S., Lamas, G. A., Buller, C. E., Dzavik, V., Reynolds, H. R., Abramsky, S. J., Forman, S., Ruzyllo, W., Maggioni, A. P., White, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066139 · Cited by 732
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Spaulding, C., Daemen, J., Boersma, E., Cutlip, D. E., & Serruys, P. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066633 · Cited by 704
Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes
de Winter, R. J., Windhausen, F., Cornel, J. H., Dunselman, P. H. J. M., Janus, C. L., Bendermacher, P. E. F., Michels, H. R., Sanders, G. T., Tijssen, J. G. P., & Verheugt, F. W. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044259 · Cited by 535
Yusuf, S. (1988) · JAMA · doi:10.1001/jama.1988.03410140100032 · Cited by 491
Katritsis, D. G., & Ioannidis, J. P. A. (2005) · Circulation · doi:10.1161/circulationaha.104.521864 · Cited by 431
Hueb, W., Soares, P. R., Gersh, B. J., César, L. A. M., Luz, P. L., Puig, L. B., Martinez, E. M., Oliveira, S. A., & Ramires, J. A. F. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.065 · Cited by 408
Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy
Henderson, R. A., Pocock, S. J., Clayton, T. C., Knight, R., Fox, K. A. A., Julian, D. G., & Chamberlain, D. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00951-3 · Cited by 359
Fox, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14974-4 · Cited by 300
Smith, S. J. (2006) · Journal of the American College of Cardiology · Cited by 300
A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results
(1982) · JAMA · doi:10.1001/jama.247.12.1707 · Cited by 291
Feldman, D. N., Gade, C. L., Slotwiner, A., Parikh, M., Bergman, G. W., Wong, S. C., & Minutello, R. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.026 · Cited by 156
Drug-Eluting Coronary Stents — Promise and Uncertainty
Curfman, G., Morrissey, S., Jarcho, J. A., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejme068306 · Cited by 99
Sample size calculation for complex clinical trials with survival endpoints
Shih, J. H. (1995) · Controlled Clinical Trials · doi:10.1016/s0197-2456(95)00132-8 · Cited by 94
Boden, W. E., O’Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M. L., Dada, M. R., Casperson, P. R., Harris, C. L., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.08.015 · Cited by 88
Self-citationBoden, W. E., O’Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M. L., Dada, M. R., Casperson, P. R., Harris, C. L., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.082 · Cited by 86
Self-citationYusuf, S. (1988) · JAMA · doi:10.1001/jama.260.14.2088 · Cited by 58
A modified log rank test for highly stratified data
Schoenfeld, D., & Tsiatis, A. A. (1987) · Biometrika · doi:10.1093/biomet/74.1.167 · Cited by 27
Weintraub, W. S., Barnett, P. G., Chen, S., Hartigan, P. M., Casperson, P. R., O’Rourke, R. A., Boden, W. E., Lewis, C., Veledar, E., Becker, E. R., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.07.035 · Cited by 26
Self-citation
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
Cited by
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Metadata
- Authors
- Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., Chaitman, B. R., Shaw, L., Gosselin, G., Nawaz, S., Title, L. M., Gau, G., Blaustein, A. S., Booth, D. C., Bates, E. R., Spertus, J. A., Berman, D. S., Mancini, G. B. J., & Weintraub, W. S.
- Affiliations
- VA Western New York Healthcare System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1503-1516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160414137
- Cited by
- 4,699
- References
- 49
- Citations by year
- 2026: 111 · 2025: 142 · 2024: 150 · 2023: 166 · 2022: 197 · 2021: 255 · 2020: 282 · 2019: 202 · 2018: 227 · 2017: 211 · 2016: 276 · 2015: 263 · 2014: 295 · 2013: 309 · 2012: 322
- FWCI
- 315.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- optimal medical therapy, percutaneous coronary intervention, stable coronary artery disease, myocardial ischemia, cardiovascular events, myocardial infarction, mortality, lifestyle intervention, coronary artery disease
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Angina Pectoris, Angiotensin-Converting Enzyme Inhibitors, Anticholesteremic Agents, Antihypertensive Agents, Combined Modality Therapy, Coronary Disease, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk Factors, Angioplasty, Balloon, Coronary, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.